| HRA002327
(Controlled Access)
|
JUPITER-06 prospectively designed a biomarker study and curated pre-treatment tumor specimens from 486 (95%) patients. Through whole-exome sequencing (WES) of these specimens, we identify genomic immune-oncologic features that were predictive of the efficacy of chemo+anti-PD-1 versus chemotherapy alone and further incorporate these features into an Esophageal cancer Genome-based Immuno-oncology Classification (EGIC) for patients with advanced ESCC. The EGIC scheme can guide future biological research on the biomarkers of response and resistance to this regimen and provide individualized treatment strategies for patients with advanced ESCC. |
